Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy

Background/Aims: Do serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 levels serve as prognostic indicators in patients with gastric cancer (GC)? This is a question that has long been disputed. The aim of this study was to evaluate the significance of perioperative serum levels of CEA and CA19-9 for predicting the recurrence and long-term survival after patients with pT2-4 GC undergo curative gastrectomy. Methods: This study included 251 patients with radically resected pT2-4 GC without preoperative treatment. Associations between the preoperative and postoperative serum levels of CEA or CA19-9 and postoperative long-term outcomes and recurrence patterns were evaluated. Results: Preoperative CEA >5.0 ng/mL was an independent prognostic factor of overall survival. Elevation of both preoperative CEA and CA19-9 levels showed no synergistic adverse effects on prognosis. Preoperative levels of these markers achieved superior predictive performance compared with the postoperative values. Adverse prognosis is significantly associated with persistent elevation of CEA levels before and after gastrectomy. Elevation of CEA levels, particularly at postoperative measurement, was significantly associated with hematogenous recurrence. Conclusion: Determination of perioperative CEA levels facilitated predictions of recurrence patterns and prognosis among patients with pT2-4 GC who underwent curative gastrectomy.

[1]  M. Kanda,et al.  Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer , 2017, Annals of Surgical Oncology.

[2]  M. Kanda,et al.  Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer , 2016, Annals of surgery.

[3]  Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2014 (ver. 4) , 2016, Gastric Cancer.

[4]  M. Kanda,et al.  Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer , 2016, Medicine.

[5]  Dazhi Xu,et al.  Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection , 2016, Oncotarget.

[6]  Wei Wang,et al.  Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma , 2016, Oncotarget.

[7]  Jun-xiu Yu,et al.  Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer. , 2016, Molecular and clinical oncology.

[8]  M. Kanda,et al.  Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer , 2016, Annals of Surgical Oncology.

[9]  M. Kanda,et al.  Function and diagnostic value of Anosmin‐1 in gastric cancer progression , 2016, International journal of cancer.

[10]  M. Kanda,et al.  Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis. , 2015, Surgery.

[11]  M. Kanda,et al.  Updated evidence on adjuvant treatments for gastric cancer , 2015, Expert review of gastroenterology & hepatology.

[12]  Chengwei Tang,et al.  The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: A Meta-Analysis Including 14651 Patients , 2015, PloS one.

[13]  Y. Suh,et al.  The Value of Postoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 Levels for the Early Detection of Gastric Cancer Recurrence after Curative Resection , 2014, Journal of gastric cancer.

[14]  D. Shin,et al.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[15]  Y. Inokawa,et al.  The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients , 2014, Surgery Today.

[16]  R. Seruca,et al.  Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? , 2014, Virchows Archiv.

[17]  Yan-Shen Shan,et al.  Management of gastric cancer in Asia: resource-stratified guidelines. , 2013, The Lancet. Oncology.

[18]  Jae Yong Cho,et al.  Molecular Diagnosis for Personalized Target Therapy in Gastric Cancer , 2013, Journal of gastric cancer.

[19]  J. Cheong,et al.  Prognostic Value of Early Postoperative Tumor Marker Response in Gastric Cancer , 2013, Annals of Surgical Oncology.

[20]  Kun-He Zhang,et al.  Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer , 2013, BMC Gastroenterology.

[21]  Yuan-Fang Li,et al.  The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy , 2013, Journal of surgical oncology.

[22]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Kim,et al.  Molecular Pathology of Gastric Carcinoma , 2011, Pathobiology.

[24]  Laura H. Tang,et al.  Molecular Classification of Gastric Cancer: A New Paradigm , 2011, Clinical Cancer Research.

[25]  M. Li,et al.  Comparison of carcinoembryonic antigen prognostic value in serum and tumour tissue of patients with colorectal cancer , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[26]  V. Heinemann,et al.  Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer , 2006, Oncology.

[27]  John R. Mackey,et al.  Gastric Adenocarcinoma: Review and Considerations for Future Directions , 2005, Annals of surgery.

[28]  U. McDermott,et al.  Molecular and biochemical markers in colorectal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Duffy CA 19-9 as a Marker for Gastrointestinal Cancers: A Review , 1998, Annals of clinical biochemistry.

[30]  K. Sugimachi,et al.  Carcinoembryonic antigen (CEA) in stage IV gastric cancer as a risk factor for liver metastasis: A univariate and multivariate analysis , 1993, Journal of surgical oncology.

[31]  Y. Kodera,et al.  Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation. , 1993, British Journal of Cancer.

[32]  Y. Maehara,et al.  Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. , 1990, Cancer research.

[33]  H. Yoshida,et al.  Immunohistochemical demonstration of carcinoembryonic antigen (CEA) on tissue sections from squamous cell head and neck cancer and plasma CEA levels of the patients. , 1986, International journal of oral and maxillofacial surgery.

[34]  M. Herlyn,et al.  Colorectal carcinoma antigens detected by hybridoma antibodies , 1979, Somatic cell genetics.

[35]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.

[36]  F. Roviello,et al.  Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. , 2004, Journal of the American College of Surgeons.

[37]  Y. Kodera,et al.  The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. , 1996, The American journal of gastroenterology.

[38]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[39]  H. Nagura,et al.  Immunohistochemical study of carcinoembryonic antigen in patients with colorectal cancer. Correlation with plasma carcinoembryonic antigen levels , 1985, Cancer.